highly

[ad_1] Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the company has strengthened its Clinical Advisory Board with three international highly experienced Key Opinion Leaders in oncology. With Professor Richard Schilsky already on board since April 2021, the Clinical Advisory Board now consists of four members. The three new members are Professor